{
  "id": 19211151,
  "title": "EyePoint at Guggenheim conference: DME becomes the main focus",
  "url": "https://urgent.news/2026/11/09/eyepoint-at-guggenheim-conference-dme-becomes-the-main-focus",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T20:02:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/eyepoint-at-guggenheim-conference-dme-becomes-the-main-focus-93CH-5013088"
  },
  "original_language": "en",
  "account": "On 09 November 2026, at the 3rd Annual Guggenheim Healthcare Innovation Conference, EyePoint Pharmaceuticals Inc. (EYPT) discussed a shift in focus from wet age-related macular degeneration (AMD) to diabetic macular edema (DME). The company's stock had plummeted 98% year-to-date, trading at $0.36 and boasting a market capitalization of $30.78 million. CEO Jay Duker and CFO George emphasized their focus on DME, where they believe DURAVYU's mechanism of action fits the disease better and the market is larger.\n\nThe wet AMD Phase III trials, LUGANO and LUCIA, failed to meet their primary endpoint of non-inferiority in visual acuity versus 2mg EYLEA. However, DURAVYU demonstrated strong safety data and meaningful secondary benefits, such as better fluid control and fewer injections. The company expects data from two Phase III DME trials, COMO and CAPRI, in very early Q4 2025. These trials include 550 patients, with a 75% treatment-naive and 25% previously treated mix. Management expressed confidence in DME, citing faster and more durable results from DURAVYU compared to wet AMD.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}